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Abstract
Background
Bothrops, Crotalus and Lachesis represent the most medically relevant genera of pitvipers
in Central and South America. Similarity in venom phenotype and physiopathological profile
of envenomings caused by the four nominal Lachesis species led us to hypothesize that an
antivenom prepared against venom from any of them may exhibit paraspecificity against all
the other congeneric taxa.
Methods
To assess this hypothesis, in this work we have applied antivenomics and immunochemi-
cal methods to investigate the immunoreactivity of three monovalent antivenoms and two
polyvalent antivenoms towards the venoms from different geographic populations of
three different Lachesis species. The ability of the antivenoms to neutralize the proteo-
lytic, hemorrhagic, coagulant, and lethal activities of the seven Lachesis venoms was
also investigated.
Results
A conspicuous pattern of immunorecognition and cross-neutralization for all effects was evi-
dent by the polyspecific antivenoms, indicating large immunoreactive epitope conservation
across the genus during more than 10 million years since the Central and South American
bushmasters diverged.
Conclusions
Despite the broad geographic distribution of Lachesis, antivenoms against venoms of differ-
ent species are effective in the neutralization of congeneric venoms not used in the
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immunization mixture, indicating that they can be used equivalently for the clinical treatment
of any lachesic envenoming.
General significance
This study demonstrates that antivenoms raised against venom of different Lachesis spe-
cies are indistinctly effective in the neutralization of congeneric venoms not used in the
immunization mixture, indicating that antivenoms against conspecific venoms may be used
equivalently for the clinical treatment of envenomings caused by any bushmaster species.
Author summary
Snakebite envenoming is a neglected public health problem in many developing countries
and antivenom administration constitutes the mainstay in the treatment of such enve-
nomings. Therapeutic antivenoms contain animal-derived antibodies against venom tox-
ins and are produced by immunizing animals with the venom from one or several snake
species from a defined geographical area. Defining the geographic boundaries of the effi-
ciency of an antivenom therefore has implications for its rational and efficient use. In
Central and South America most accidents are caused by pitvipers of the genus Bothrops,
Crotalus and Lachesis. There are four Lachesis species distributed in a variety of habitats
ranging from the Caribbean coast of Central America to the Atlantic rainforest of Brazil.
Lachesis species cause severe envenomings in humans due to the toxicity of their venoms
and also to the large amount of venom they inject into their victims. In this work we inves-
tigate the capability of several antivenoms to neutralize the toxic activities of a panel of
Lachesis venoms. The results demonstrate that antivenoms raised by immunizing horses
with the venoms of different Lachesis species are effective at neutralizing congeneric ven-
oms not used in the immunization, indicating that they could be used equivalently for the
clinical treatment of any lachesic envenoming.
Introduction
Snakebite envenoming is a public health issue and a neglected disease in many tropical and
sub-tropical regions of Africa, Asia, Latin America and Oceania, especially affecting the most
impoverished and geopolitically disadvantaged rural communities [1–4]. Between 1.2 and 5.5
million people are victims of snakebites every year, leading to 95.000–125.000 deaths and leav-
ing more than 400.000 people with permanent physical and psychological sequelae [4–7]. In
Central and South America most accidents are caused by pitvipers of the Viperidae family,
subfamily Crotalinae, with Bothrops, Crotalus and Lachesis being the most medically relevant
genera.
Genus Lachesis comprises the longest pitvipers in the world, with adults ranging in length
from 2 to 2.5 m. The four nominal species of this genus, L. stenophrys (Central American bush-
master), L. melanocephala (Black-headed bushmaster), L. acrochorda (Chocoan busmaster)
and L. muta (South American bushmaster) inhabit remote forested areas of Central and South
America, and on the island of Trinidad [8–10]. Central and South American populations of
Lachesis diverged around 18.0–6.5 Mya, with a later split between L. melanocephala and L. ste-
nophrys taking place 11–4 Mya, while differentiation of South American lineages occurred
800.000 to 300.000 years ago [8]. L. stenophrys is distributed through the Caribbean coast of
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Nicaragua, Costa Rica and Panama; L. melanocephala is found in the Pacific versant of south-
western Costa Rica, and the extreme western regions of Panama; L. acrochorda inhabits both
the Atlantic and Pacific versants of western Panama and into northwestern Colombia, on the
Atlantic coast, where it extends southward into the Cauca and Magdalena rivers valleys, and
along the Pacific versant of Colombia into northwestern Ecuador. L. muta is the most widely
distributed species of the genus, including the equatorial forest east of the Andes, from Colom-
bia, eastern Ecuador, Peru, northern Bolivia, eastern and southern Venezuela to Guyana, Suri-
nam, French Guiana and most of northern Brazil [10]. Two subspecies of L. muta are
reported: L. m. muta and L. m. rhombeata, with an exclusive distribution of the latter subspe-
cies in the Atlantic forest of eastern-center of Brazil. Based on morphology, some authors con-
sider that there are populations of L. m. rhombeata in the Amazonia basin [11].
Human bites by Lachesis species are not frequent but when occur cause severe envenoming
due to large amount of venom (200–411 mg) injected into the victim and also owing to its tox-
icity in humans, as reported for snakebites in Brazil, Colombia and Costa Rica [11–21]. Com-
mon local effects include agonizing burning-throbbing pain, mild hemorrhage, edema, and
blister formation. These signs and symptoms are accompanied by systemic alterations, such as
hemorrhage, coagulopathy, cardiovascular collapse, and by the so-called “Lachesis syndrome”,
an alteration of the autonomic nervous system which manifests with profuse sweating, abdom-
inal colic, nausea, recurrent vomiting, watery diarrhea, diastolic and systolic hypotension, and
sinus bradycardia, together with sensorial disorders (uncoordinated march, lapses of uncon-
sciousness) and serious hemodynamic alterations within 15–20 min after a bite [12–19, 22].
Comprehensive transcriptomic and proteomic studies across Lachesis [23–26] have
revealed remarkably similar venom phenotypes comprising seven or eight toxin families,
including bradykinin-potentiating/C-type natriuretic peptide (BPPs/C-NP), Zn2+-dependent
snake venom (SV) metalloproteinase (SVMP), serine protease (SVSP), phospholipase A2
(PLA2), L-amino acid oxidase (LAOs), C-type lectin-like (CTL), and in venoms of the South
American species, also cysteine-rich secretory protein (CRISP). Ontogenetic changes in the
toxin composition of L. stenophrys venom result in the net shift from a BPPs/C-NP-rich and
SVSP-rich venom in newborns and 2-years-old juveniles to a (PI>PIII) SVMP-rich venom in
adults [24].
The high conservation of the overall composition of Central and South American bushmas-
ter venoms and their qualitatively similar pathophysiological profile observed in clinical set-
tings [14,17,27–29], suggested that antivenoms generated against any conspecific Lachesis
venom may exhibit paraspecific protection against the toxic activities of all other Lachesis spe-
cies [24,25]. The aim of the present work was to assess this hypothesis. To this end, we carried
out a comparative study of the cross-reactivity, neutralization of toxic activities and immu-
noaffinity antivenomic profiles towards a panel of Lachesis venoms of two commercial poly-
specific antivenoms (BCL), manufactured at Instituto Clodomiro Picado, Costa Rica, against a
mixture of L. stenophrys, Bothrops asper, and Crotalus simus venoms, and antivenom produced
at Instituto Vital Brazil, Brazil, against venoms from L. m. rhombeata and five bothropic spe-
cies (BL), and experimental monospecific antivenoms AL, AB, and AC, generated, respec-
tively, against venoms of adult Costa Rican L. stenophrys, B. asper, and C. simus.
Methods
Ethics statement
All the procedures involving the use of animals in this study were approved by the Institutional
Committee for the Care and Use of Laboratory Animals (CICUA) of Universidad de Costa
Rica (approval number CICUA 028–13), and meet the Animal Research Reporting in vivo
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Experiments (ARRIVE) guidelines, and the International Guiding Principles for Biomedical
Research Involving Animals of the Council of International Organizations of Medical Sciences
(CIOMS).
Snake venoms and antivenoms
Lachesis venoms were obtained from different geographic areas of Central and South America.
Venom from L. stenophrys (Central American bushmaster) was pooled from more than 25
adult (>5 years old) snakes maintained in the herpetarium of Instituto Clodomiro Picado
(ICP, San Jose´, Costa Rica). Venom from L. melanocephala (black-headed bushmaster) was
pooled from two adult specimens maintained at Instituto Nacional de Biodiversidad (San Jose´,
Costa Rica). L. muta muta (South American bushmaster) venoms pooled from adult speci-
mens from Colombia, Peru, and Cascalheria and Tucurui regions of Brazil were kindly pro-
vided by Dr. Marı´a de Fatima D. Furtado (Instituto Butantan, São Paulo, Brazil). Samples of L.
muta rhombeata (Atlantic forest bushmaster) venom pooled from adult specimens were a gen-
erous gift from Dr. Marı´a de Fatima D. Furtado of Instituto Butantan and from Instituto Vital
Brazil (IVB, Nitero´i, Rio de Janeiro, Brazil). All venoms were lyophilized and stored at -20˚C
until used.
Commercial polyspecific BCL antivenom (batch 4800611POLQ) was manufactured by the
Industrial Division of Instituto Clodomiro Picado (San Jose´, Costa Rica) from the plasma of
horses hyperimmunized with a mixture of venoms of Costa Rican Bothrops asper, Crotalus
simus and Lachesis stenophrys [30, 31], and consists of whole IgGs purified by caprylic acid
fractionation [32]. BL antivenom (batch 125901) from Instituto Vital Brazil (Nitero´i, RJ, Bra-
zil) was produced in horses hyperimmunized with a mixture of venoms from L. m. rhombeata
and a mixture of five bothropic species, B. jararaca (50%), B. jararacussu (12.5%), B. moojeni
(12.5%), B. alternatus (12.5%) and B. neuwiedi (12.5%), and consists of purified F(ab’)2 frag-
ments generated by digestion with pepsin of ammonium sulfate-precipitated IgG molecules
[33]. Experimental monospecific AB, AC, and AL antivenoms were prepared by the Industrial
Division of Instituto Clodomiro Picado from plasma of horses subjected to a single round of
immunization with venoms of Costa Rican adult B. asper (from the Pacific and Caribbean ver-
sants of Costa Rica), adult C. simus, and adult L. stenophrys, respectively, as described [33].
These monospecific antivenoms are also whole IgG preparations prepared by caprylic acid
precipitation [33]. BCL and BL antivenoms are used therapeutically in the clinical manage-
ment of Lachesis envenomings in Central America and Brazil, respectively. Monospecific AC,
AB and AL antivenoms were developed for experimental use. For in vitro and in vivo assays
the protein concentration of antivenoms was adjusted to 50 mg/mL.
ELISA (Enzyme-linked immunosorbent assays)
96-well plates (Dynatech Immulon, Alexandria, VA) were coated overnight at 4˚C with Lach-
esis venoms (0.5 μM/well) in 0.1 M Tris, 0.15 M NaCl, pH 9.0 buffer. The plates were blocked
for 1h with 2% bovine serum albumin (BSA) in 20 mM phosphate, 135 mM NaCl, pH 7.4
(PBS) at room temperature. Purified antivenom immunoglobulins were serially diluted by a
factor of 3 (starting from a dilution of 1/500) in PBS containing 1% BSA, and added to the
wells for 1 h at room temperature. The plates were washed four times with washing buffer (50
mM Tris, 150 mM NaCl, 20 μM ZnCl2, 1 mM MgCl2, pH 7.4), and anti-horse IgG-phospha-
tase-conjugate (Sigma, St. Louis, MO, USA), diluted 1:20,000 with PBS containing 1% BSA,
was added and incubated for 1 h at room temperature. The plates were washed and developed
with p-nitrophenylphosphate in diethanolamine buffer (1 mM MgCl2, 90 mM diethanolamine,
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pH 9.8). Absorbance at 405 nm was recorded after 90 min using a microplate reader (Multis-
kan Labsystems Ltd., Helsinki, Finland).
Two-dimensional electrophoresis
L. stenophrys venom proteins were separated by two-dimensional electrophoresis (2DE) using
an Ettan IPGphor III instrument (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). For iso-
electric focusing, 300–350 μg of total venom proteins in 200 μL DeStreak Rehydration Solution
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden) including 10 mM DTT and 0.5% IPG
buffer pH 3–10 NL (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) were loaded on a 11
cm IPG strip, pH 3–10 (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) and then focused
using the following electrophoretic conditions: 500 V for 30 min, 1000 V for 30 min and 5000
V for 80 min. After isoelectric focusing, SDS-PAGE was performed under reducing conditions
in 4–15% Criterion TGX precast 11 cm gels (Bio-Rad, USA). An unstained protein molecular
weight marker (Fermentas) was included in the analysis. Gels were stained using Bio-Safe Coo-
massie Stain (Bio-Rad, USA) or PlusOne Silver Staining Kit (GE Healthcare AB, Uppsala, Swe-
den) following the manufacturer´s instructions, and images were taken with Chemidoc XRS
imaging system (BioRad, USA). Spot identification was done using the collaborative bioimage
informatics platform Icy [34] and quantified as relative density percentage using ImageJ soft-
ware [35].
Western blot analysis
2DE gels of 350 μg L. stenophrys venom proteins were transferred to polyvinylidene fluoride
(PVDF) membranes at 50 mA in a Criterion Blotter instrument (Bio-Rad, USA) overnight. To
assess transfer efficiency, PVDF membranes were previsualized by reversible Ponceau-S Red
staining. Unoccupied membrane protein-binding sites were blocked with 2% casein in TBS-T
(Tris-buffered saline with Tween 20, pH 7.6) for 30 min at room temperature, and the mem-
branes were incubated for 1 h with 1/1000 dilution of antivenoms in TBS-T containing 1%
casein. After five washing steps (5 min each) with TBS-T, the membranes were incubated for 1
h at room temperature with rabbit anti-horse IgG-peroxidase conjugate (1:15000 dilution;
Sigma-Aldrich, St. Louis, USA). Purified antibodies from non-immunized horses were used as
control. After washing off unbound secondary antibodies, the immunoreactive spots were
visualized using a chemiluminescence substrate (Invitrogen, USA). Images were taken with
Chemidoc XRS imaging system (BioRad, USA) and protein spots of interest were analyzed
using ImageJ software.
Protein identification by MALDI-TOF-TOF MS
2DE protein spots were excised and subjected to reduction (10 mM dithiothreitol), alkylation
(50 mM iodoacetamide), and overnight in-gel digestion with sequencing grade trypsin
(Sigma), in 50 mM ammonium bicarbonate at 37˚C. Tryptic peptide digests were extracted in
50% acetonitrile containing 1% trifluoroacetic acid (TFA), and analyzed by MALDI-TOF-TOF
MS using an AB4800-Plus Proteomics Analyzer (Applied Biosystems). To this end, tryptic
digests were mixed with an equal volume of α-cyano-hydroxycinnamic acid saturated in 50%
acetonitrile, 0.1% TFA, and 1 μL spotted onto an Opti-TOF 384-well plate, dried, and analyzed
in positive reflector mode. TOF MS spectra were acquired using 500 shots at a laser intensity
of 3000. TOF/TOF fragmentation spectra were acquired (500 shots at a laser intensity of 3900)
for the ten most intense precursor ions. External calibration in each run was performed with
CalMix standards (ABSciex) spotted onto the same plate. Fragmentation spectra were searched
against the UniProt/SwissProt database (taxonomy: Serpentes) using the ProteinPilot v.4 and
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the Paragon algorithm (ABSciex) at95% confidence, or manually interpreted and the
deduced sequences BLASTed against the NCBI (http://blast.ncbi.nlm.nih.gov) non-redundant
database for protein class assignment by similarity.
Antivenomics
The immunoreactivity of poly- and monospecific antivenoms towards the different Lachesis
venoms was assessed using a second-generation antivenomics approach [36]. To prepare the
antivenom affinity column, 200 μL of NHS-activated Sepharose 4 Fast Flow (GE Healthcare
Bio-Sciences AB, Uppsala, Sweden) matrix was packed in a Pierce centrifuge column and
washed with 15 matrix volumes of cold 1 mM HCl followed by two matrix volumes of 0.2 M
NaHCO3, 0.5 M NaCl, pH 8.3 (coupling buffer) to adjust the pH of the column to 7.0–8.0.
Antivenoms were dialysed against MilliQ water, lyophilised, and reconstituted in coupling
buffer. The concentration of the antivenom stock solutions was determined spectrophotomet-
rically using an extinction coefficient of 1.36 for a 1 mg/mL concentration of Fab at 280 nm
using a 1 cm light pathlength cuvette. Twenty milligrams of polyspecific BCL antivenom, 15
mg of BL antivenom, and 35–50 mg of monospecific AC, AB and AL antivenoms were dis-
solved in a half matrix volume of coupling buffer and incubated with the matrix for 4 h at
room temperature. Antivenom coupling yield was estimated measuring the non-bound anti-
venom by quantitative band densitometry of SDS-PAGE (MetaMorph software, MDS Analyti-
cal Technologies) using as standard for the linear range the pre-coupled antivenom. After the
coupling, any remaining active groups were blocked with 200 μL of 0.1 M Tris–HCl, pH 8.0 at
4˚C overnight using an orbital shaker. The affinity column was washed alternately at high and
low pH, with three volumes of 0.1 M acetate buffer, 0.5 M NaCl, pH 4.0–5.0 and three volumes
of 0.1 M Tris–HCl buffer, pH 8.5. This treatment was repeated six times and the column was
equilibrated in binding buffer (20 mM phosphate, 135 mM NaCl, pH 7.4, PBS). For the immu-
noaffinity assay, 200 μg of venoms from L. stenophrys (Costa Rica), L. melanocephala (Costa
Rica), L. m. rhombeata (Recife, Brazil), and L. m. muta from Colombia, Peru and Brazil
(Tucurui and Cascalheira regions), dissolved in 1⁄2 matrix volume of PBS, were loaded and
incubated for 1 h at room temperature with the affinity matrix, followed by incubation in an
orbital shaker overnight at 4˚C. As specificity controls, 200 μL of Sepharose 4 Fast Flow matrix,
without or with 8.5 mg of immobilized pre-immune IgGs, were incubated with venom and
developed in parallel to the immunoaffinity columns. Non-retained fractions were collected
with 5 matrix volumes of PBS, and the immunocaptured proteins were eluted with 5 matrix
volumes of elution buffer (0.1 M glycine-HCl, pH 2.0) and neutralised with 150 μL 1 M Tris-
HCl, pH 9.0. The non-retained and the immunocaptured venom fractions were lyophilized,
reconstituted in 40μl of MilliQ water, and fractionated by reverse-phase HPLC using a Discov-
ery BIO Wide Pore C18 (15 cm x 2.1 mm, 3 μm particle size, 300 Å pore size) column using an
Agilent LC 1100 High Pressure Gradient System equipped with a DAD detector and micro-
auto sampler. The column was developed at a flow rate of 0.4 mL/min and proteins eluted with
a linear gradient of 0.1% TFA in MilliQ water (solution A) and 0.1% TFA in acetonitrile (solu-
tion B): isocratic at 5% solution B for 1 min, followed by 5–25% solution B for 5 min, 25–45%
solution B for 35 min, and 45–70% solution B for 5 min. Protein was detected at 215 nm with a
reference wavelength of 400 nm.
Neutralization of venom activities
Polyspecific and monospecific antivenoms were assessed for their ability to neutralize the
lethal, hemorrhagic, coagulant and proteolytic activities of venoms. The protein concentration
of all antivenoms was adjusted to 50 mg/mL, as determined using a NanoDrop 2000 (Thermo
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Fischer Scientific, DE, USA). For the neutralization assays, a fixed dose of venom (“challenge
dose”), dissolved in PBS, was incubated with various dilutions of antivenom. Controls includ-
ing venom solutions incubated with PBS instead of antivenom were used. The venom/anti-
venom mixtures and controls were incubated for 30 min at 37˚C and then tested in the
experimental systems described below and detailed in previous publications [37,38]. Neutraliz-
ing ability was expressed as Median Effective Dose (ED50), defined as the μL antivenom/mg
venom ratio in which the activity of venom was reduced by 50% [39]. In the case of coagulant
activity, neutralization was expressed as Effective Dose (ED), defined as the antivenom/venom
ratio in which the clotting time of plasma was prolonged three times when compared with
clotting time of plasma incubated with venom alone [40].
All the in vivo experiments were performed in CD-1 mice, and the protocols were approved
by the Institutional Committee for the Care and Use of Laboratory Animals (CICUA) of the
University of Costa Rica. Lethality was assessed by the intraperitoneal route in 16–18 g mice
and a challenge dose corresponded to 3 Median Lethal Doses (LD50) was used for the neutrali-
zation tests [37]. An arbitrary level of 500 μL antivenom/mg venom was selected to evaluate
the efficacy of antivenoms for neutralizing lethality. Only this antivenom/venom ratio was
used owing to the scarcity of some venoms and also for reducing the number of mice used.
Death of mice was recorded at 48 h. Hemorrhagic activity was evaluated by using the rodent
skin test using 18–20 g mice and a challenge venom dose corresponding to 10 Minimum Hem-
orrhagic Doses (MHD) [41]. Coagulant activity was assessed on citrated human plasma and
the challenge dose used was 2 Minimum Coagulant Doses (MCD) [40]. Proteolytic activity
was determined using azocasein (Sigma, USA) as substrate, as described by Gutie´rrez et al.
[42]. For neutralization tests, a challenge dose was selected, corresponding to the amount of
venom that induced a change in absorbance of 0.75 at 450 nm. A summary of reference venom
activities (Median Lethal Dose, Minimum Hemorrhagic Dose, Minimum Coagulant Dose and
challenge dose for proteolytic activity) of Lachesis venoms are listed in Table 1.
Statistical analyses
The results of neutralization assays of venom activities were compared by ANOVA, followed
by Tukey test for specific comparisons between means of pairs of groups. A p value <0.05 was
Table 1. Reference doses of Lachesis venoms considered in the study.
Venom LD50 [μg] MHD [μg] MCD [μg] Challenge dose
(proteolysis) [μg]
L. stenophrys (CR) 88.6 (69.8–112.3)a 2.10 ± 0.4b 6.00 ± 0.9 a 10
L. melanocephala (CR) 103c 0.70 ± 0.06 c 6.77 ± 0.13 20
L. m. muta (Colombia) 121.6 (98.7–164.6)a 0.66 ± 0.13a 8.10 ± 1.6 a 15
L. m. muta (Peru) 192.4 (170.2–207.4) 0.096 ± 0.02 4.46 ± 0.08 20
L. m. muta (Cascalheira, Br) 72.7 (56.4–93.9)a 0.23 ± 0.03a 5.20 ± 0.3a 20
L. m. muta (Tucurui, Br) 107.2 (82.0–140.3)a 0.77 ± 0.20a 8.70 ± 2.4a 10
L. m. rhombeata (Recife, Br) 122.8 (94.3–160)a 0.95 ± 0.12a 2.50 ± 0.6a 15
LD50: Median Lethal Dose; MHD: Minimum Hemorrhagic Dose; MCD: Minimum Coagulant Dose (see text for details).
All challenge doses for proteolytic activity were calculated according to [42].
LD50, MHD and MCD for L. muta muta venom from Peru, and MCD for L. melanocephala venom are those previously described in [55].
a[56]
b[57]
c[29].
https://doi.org/10.1371/journal.pntd.0005793.t001
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regarded as statistically significant. For data not following the assumptions of parametric tests,
a Kruskal-Wallis test was used, followed by Dunn test. The analysis was performed using the
Minitab (v 16.1.0, 2010) statistic program.
Results and discussion
Venom represents a trophic adaptive trait that plays key roles in the organismal ecology
and evolution of advanced snakes [43,44]. The well-documented geographic variability of
snake venoms at all taxonomic levels [45] may contribute to the snake’s capability to adapt
to different ecological niches, but at the same time imposes an added difficulty to the pro-
duction of antidotes to counteract the toxic activities of snakebite envenomings. The par-
enteral administration of an effective antivenom constitutes the mainstay in the treatment
of snakebite envenomings [46,47]. Defining the geographic boundaries of the efficiency of
an antivenom, even against disjunct populations of the same nominal species, has implica-
tions for its rational and efficient use. In this regard, unveiling the immunological profile
of an antivenom towards the landscape of congeneric venom phenotypic variation provides
the necessary knowledge-informed ground for assessing whether it is clinically justified the
generation of a new antivenom for a specific geographic region, or if the deployment of an
existing antivenom to a new geographical setting can be recommended. This is particularly
relevant for widely distributed species, such as those comprising the genus Lachesis, which
can be found in disjunct habitats ranging from the Caribbean coast of Central America to
the Atlantic rainforest of Brazil (see Fig 1 in [24]). The combination of venom neutraliza-
tion tests and antivenomics constitutes a powerful toolbox for evaluating an antivenom’s
preclinical efficacy [48–51]. Using this platform we have investigated the capability of two
therapeutic polyvalent antivenoms and three experimental monospecific antivenoms to
neutralize the hemorrhagic, coagulant, proteolytic and lethal activities of homologous and
heterologous Lachesis venoms.
Immunoreactivity profile of Lachesis antivenoms by ELISA and 2DE
immunoblotting analysis
Initial assessment of the immunoreactivity of the commercial polyspecific BCL and BL anti-
venoms, and the experimental monospecific B, C and L antivenoms, against antigens present
in the venoms of Costa Rican L. stenophrys and L. melanocephala, Brazilian L. m. rhombeata
(Recife) and L. m. muta from different geographic locations (Colombia, Peru, and Brazil [Cas-
calheira and Tucurui]) were done by ELISA and 2DE immunoblotting analysis.
No significant differences were found in the levels of specific antibodies against Lachesis
venoms present in the BCL antivenom, and the AB and AL antivenoms (S1 Fig). The high-
est titer corresponded to the binding of BL antivenom to L. stenophrys, L. m. muta (Colom-
bia), L. m. muta (Cascalheira), and L. m. rhombeata (Recife) venoms, whereas the titer of
this antivenom against venoms from L. melanocephala, L. m. muta (Peru) and L. m. muta
(Tucurui) was indistinguishable from that of the BCL antivenom (S1 Fig). Monospecific
AC antivenom exhibited the lowest reactivity against the seven Lachesis venoms analyzed
(S1 Fig).
The spectrum of L. stenophrys toxins immunorecognized by the poly- and monospecific
antivenoms was investigated by 2DE and immunoblot analysis. Fig 1A displays a 2DE ref-
erence map and the MALDI-TOF-TOF MS protein assignments are listed in S1 Table. In
concordance with ELISA results, Western blot analyses revealed extensive protein spot rec-
ognition by all the five antivenoms (Fig 1B and S2 Table), particularly for spots in the range
of 25–35 kDa (serine proteinases, SVSPs) and 14–16 kDa (phospholipases A2 (PLA2) and
Immunoreactivity and neutralization of Lachesis venoms by anti
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Galactose-binding lectin). Polyspecific BL and monospecific AB antivenoms showed also
strong immunoreactivity towards protein spots of apparent molecular mass 55–80 kDa,
which were identified as snake venom metalloproteinases of class PIII (PIII-SVMP) and
L-amino acid oxidase (LAO) molecules. However, all the antivenoms showed weak
Fig 1. Panel A. 2DE protein map of adult L. stenophrys venom. 350 μg of venom was separated on an 11 cm
IPG strip with a pH gradient from 3 to 10 (first dimension) and on a 4–15% SDS-polyacrylamide Criterion TGX
gel as second dimension. Proteins were stained with Coomassie Blue. Isoelectric point (IP), apparent Mw,
and relative spot intensity were computed using software ImageJ. Protein identification was accomplished by
MALDI-TOF-TOF MS. Protein spot features are listed in S1 Table. Panel B. Electroblotted 2DE separated
venom proteins from adult L. stenophrys probed against commercial polyspecific BCL antivenom; BL
antivenom; and monoespecific AL, AB, and AC antivenoms. Protein identifications by MALDI-TOF/TOF MS
are listed in S1 Table (Supplementary Materials).
https://doi.org/10.1371/journal.pntd.0005793.g001
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immunostaining of spot 64 containing the major SVMP of class PI (PI-SVMP). Weak
immunorecognition of PI-SVMPs has been also reported for other antibothropic antiven-
oms [52,53].
Immunoreactivity profile of antivenoms by immunoaffinity-based
antivenomics
Second generation antivenomics [36] was applied to complement the ELISA and Western blot
analyses of the immunoreactivity of the lachesic antivenoms towards the panel of Lachesis ven-
oms used for this study. Figs 2–8 display the immunoaffinity chromatography-based antive-
nomic profiles of commercial BCL and BL polyspecific antivenoms and monospecific B, L,
and C experimental antivenoms towards the venoms of L. stenophrys and L. melanocephala
from Costa Rica, L. muta muta from Colombia, Peru, and the Brazil regions of Cascalheria,
Tucurui, and L. muta rhombeata from Recife, Brazil. The results show impaired immunocap-
turing ability of the early eluting chromatographic fractions comprising bradykinin-potentiat-
ing-like peptides (BPP-like) by all the antivenoms. Although together these fractions account
for about 1/3 by weight of total venom components, previous investigations have shown that
the intraperitoneal administration of an amount of BPP-like peptides contained in 10–24
LD50s of venom induced neither a significant change in the mean arterial blood pressure of
mice, nor signs of abnormal behavior, or histopathological alterations in heart and lungs [25].
These observations strongly suggest that, despite being a major venom component, the BPP-
Fig 2. Immunoaffinity chromatography-based antivenomic analysis of the immunoreactivity of
polyspecific and monospecific antivenoms towards the venom of L. stenophrys from Costa Rica.
Panels display reverse-phase separations of whole venom components, and non-retained (A, C, E, G, and I)
and the retained (B, D, F, H, and J) fractions recovered, respectively, from the affinity columns of immobilized
BCL, BL, AL, AB, and AC antivenoms. Panels K and L, non-retained and retained venom fractions by
immobilized equine control immunoglobulins. BPP, bradykinin-potentiating peptide; DISI, disintegrin; VEGF,
vascular endothelial growth factor; PLA2, phospholipase A2; Gal, galactose-binding lectin; SVSP, snake
venom serine proteinase; LAO, L-amino acid oxidase; PI and PIII, snake venom metalloproteinase (SVMP) of
class PI and PIII, respectively.
https://doi.org/10.1371/journal.pntd.0005793.g002
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like peptides by themselves may not represent a serious clinical concern in the treatment of
Lachesis envenomings. The interpretation of these results has to consider that certain antigens
may become denatured during reverse-phase separation and, henceforth, some conforma-
tional epitopes might be lost.
Except for the BPPs, both polyspecific antivenoms efficiently immunocaptured all the com-
ponents from L. stenophrys (Fig 2), L. m. muta (Colombia) (Fig 4) and L. m. rhombeata (Fig 8)
venoms. In addition, the BL antivenom immunocaptured the venom components of L. m.
muta from the Brazilian localities Cascalheira (Fig 6) and Tucurui (Fig 7). The apparent low
recovery of PI- and PIII-SVMPs (eluting from the RP-HPLC column at 40–42 min) in the
immunoaffinity captured fractions of the BCL and BL affinity columns (Figs 2–8, panels B and
D, respectively) may be ascribed to the high affinity of these venom proteins for the antivenom
molecules, as has been demonstrated in a previous work [25].
The worst immunocapturing profile of BCL and BL antivenoms was obtained using L. m.
muta from Peru (Fig 5), where Gal-lectin [Q9PSM4] eluting in peak 9 (Fig 5) was essentially
(>85%) found in the non-binding fraction. The BCL antivenom also showed limited binding
capability towards Gal-lectin [Q9PSM4] and serine proteinase [P33589] from L. m. muta from
Cascalheira (peaks 9 and 11, respectively, Fig 6A; 65% of each proteins found in the not
retained fraction) and Tucurui (peaks 8 and 10, respectively, Fig 7A, 53% not immunocap-
tured), and the PLA2 molecule eluting in peak 3 of L. m. muta from Tucurui (Fig 7A). 27% of
this protein was not immunocaptured by the BCL antivenom.
Monospecific antivenoms showed significantly more limited immunorecognition profiles
than BCL and BL antivenoms toward venoms of all Lachesis taxa investigated. The three
Fig 3. Immunoaffinity chromatography-based antivenomic analysis of the immunoreactivity of
polyspecific and monospecific antivenoms towards the venom of L. melanocephala from Costa Rica.
Panels display reverse-phase separations of whole venom components, and non-retained (A, C, E, G, and I)
and the retained (B, D, F, H, and J) fractions recovered, respectively, from the affinity columns of immobilized
BCL, BL, AL, AB, and AC antivenoms. Panels K and L, non-retained and retained venom fractions by
immobilized equine control immunoglobulins. Protein acronyms as in the legend of Fig 2.
https://doi.org/10.1371/journal.pntd.0005793.g003
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monospecific antivenoms, but particularly the anti-crotalic (AC) antivenom, exhibited poor
binding ability towards most venom proteins, including PLA2s, CRISP, Gal-lectin, SVSPs, PI-
and PIII-SVMPs and LAO. The average toxin immunocapturing activity of this monospecific
antivenom was 16% (L. stenophrys), 21% (L. melanocephala,), 21% (L. m. muta Colombia), 9%
(L. m. muta Peru), 9% (L. m. muta Cascalheira), 17% (L. m. muta Tucurui), and 19% (L. m.
rhombeata) (panels I of Figs 2–8, respectively).
Although a comparison of the levels of immune recognition gathered from antivenomics
with the in vivo neutralization capacity of an antivenom is not straightforward, since both
experiments involve radically different protocols, in our experience, an immunocapturing
capability of25% of total viperid venom proteins correlates with a good outcome in in vivo
neutralization tests [48–51]. As a whole, the antivenomics evidence reinforce our view that
both polyspecific BCL and BL antivenoms are likely to be effective in the neutralization of het-
erologous congeneric venoms, thus supporting their use for the treatment of Lachesis enve-
nomings throughout the range of distribution of these snakes. In addition, the fact that
antivenoms BCL, and particularly BL, are more effective than the monospecific AL antivenom,
even against the homologous L. stenophrys venom, seems to indicate that the inclusion of
botropic venoms in the immunization mixture aided in the generation of antibodies exhibiting
paraspecificity against Lachesis toxins. This combination of immunogens seems to be a more
appropriate formulation than a single venom for the treatment of envenomings by Lachesis
species.
Fig 4. Immunoaffinity chromatography-based antivenomic analysis of the immunoreactivity of
polyspecific and monospecific antivenoms towards the venom of L. muta muta from Colombia.
Panels display reverse-phase separations of whole venom components, and non-retained (A, C, E, G, and I)
and the retained (B, D, F, H, and J) fractions recovered, respectively, from the affinity columns of immobilized
BCL, BL, AL, AB, and AC antivenoms. Panels K and L, non-retained and retained venom fractions by
immobilized equine control immunoglobulins. CRISP, cysteine-rich secretory protein. Other protein acronyms
as in the legend of Fig 2.
https://doi.org/10.1371/journal.pntd.0005793.g004
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Neutralization of enzymatic and toxic activities of Lachesis venoms
Standard neutralization assays were performed to assess the extent of neutralization of proteo-
lytic, hemorrhagic, procoagulant and lethal activities [39–41]. Despite the fact that all antiven-
oms were standardized for having a protein concentration of 50 mg/mL, two aspects need to
be considered when comparing the values of neutralization experiments: (a) Most antivenoms
are made of whole IgG molecules, whereas one of them is made of F(ab’)2 fragments; hence,
for the same amount of protein, the number of molecules present in an IgG antivenom is 1.5
times lower than in a F(ab‘)2 antivenom; and (b) only an unknown proportion of all IgGs or F
(ab’)2 fragments are specific against venom components. Hence, quantitative conclusions
drawn by comparing the neutralizing abilities of different type of antivenoms should be
regarded as gross estimates.
Proteolytic activity
The BCL and the BL therapeutic antivenoms, and the monospecific AL antivenom effec-
tively neutralized the proteolytic activity of venoms from the 7 Lachesis taxa investigated
(Table 2). The BL antivenom showed higher neutralization activity than the other anti-
venoms used in this study (Table 2). The AC monospecific antivenom was only able to
neutralize the proteolytic activity of L. melanocephala venom (Table 2). The AB mono-
specific antivenom was unable to neutralize the proteolytic activity of any of the venoms
(Table 2).
Fig 5. Immunoaffinity chromatography-based antivenomic analysis of the immunoreactivity of
polyspecific and monospecific antivenoms towards the venom of L. muta muta from Peru. Panels
display reverse-phase separations of whole venom components, and non-retained (A, C, E, G, and I) and the
retained (B, D, F, H, and J) fractions recovered, respectively, from the affinity columns of immobilized BCL,
BL, AL, AB, and AC antivenoms. Panels K and L, non-retained and retained venom fractions by immobilized
equine control immunoglobulins. CRISP, cysteine-rich secretory protein; CTL, C-type lectin-like; other
acronyms as in the legend of Fig 2.
https://doi.org/10.1371/journal.pntd.0005793.g005
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Hemorrhagic activity
The BCL and BL antivenoms, and the monospecific L antivenom effectively neutralized the hem-
orrhagic activity of all the Lachesis venoms studied (Table 3). The BL antivenom showed the
highest neutralization capacity of the hemorrhagic activity than any of the other antivenoms
used in this study (Table 3). The monospecific AB antivenom was only able to neutralize the
hemorrhagic activity of L. stenophrys and L. melanocephala venoms, whereas the monospecific
AC antivenom was unable to neutralize the hemorrhagic activity of any of the venoms (Table 3).
Coagulant activity
The BCL and BL polyspecific antivenoms, and the monospecific L antivenom effectively neu-
tralized the coagulant activity of Lachesis venoms from the seven bushmaster taxa sampled
(Table 4). The BL antivenom showed the highest coagulant neutralization activity than any of
the other antivenoms use in this study (Table 4). On the other hand, neither the AB nor the
AC monospecific antivenoms were able to neutralize the coagulant activity of any of the Lach-
esis venoms used in this study (Table 4). These data agree with a previous work showing the
inefficacy of monospecific bothropic antivenom in the neutralization of the coagulation activ-
ity of L. m. muta venom [54].
Lethal activity
At the antivenom/venom ratio of 500 μL antivenom/mg venom, the BCL and BL polyspecific
antivenoms and the monospecific L antivenom, effectively neutralized the lethal activity of the
Fig 6. Immunoaffinity chromatography-based antivenomic analysis of the immunoreactivity of
polyspecific and monospecific antivenoms towards the venom of L. muta muta from Cascalheira
(Brazil). Panels display reverse-phase separations of whole venom components, and non-retained (A, C, E,
G, and I) and the retained (B, D, F, H, and J) fractions recovered, respectively, from the affinity columns of
immobilized BCL, BL, L, B, and C antivenoms. Panels K and L, non-retained and retained venom fractions by
immobilized equine control immunoglobulins. CRISP, cysteine-rich secretory protein; other acronyms as in
the legend of Fig 2.
https://doi.org/10.1371/journal.pntd.0005793.g006
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seven Lachesis venoms investigated (Table 5). The monospecific AB antivenom only neutral-
ized the lethal activity of L. stenophrys, L. muta muta (Cascalheira) and L. muta rhombeata
(Recife) (Table 5), while the monospecific AC antivenom was unable to neutralize the lethal
activity of any of the Lachesis venoms studied at the ratio of 500 μL antivenom/mg venom
(Table 5).
Concluding remarks
Snakes from the Lachesis genus cause severe envenomings in humans and are widely dis-
tributed in a variety of habitats ranging from the Caribbean coast of Central America to the
Atlantic rainforest of Brazil. Based on the high conservation of the overall protein composi-
tion of Lachesis venoms and their qualitatively similar pathophysiological profile observed
in experimental envenomings and clinical settings we have suggested that antivenoms gen-
erated against any conspecific Lachesis venom may exhibit paraspecific protection against
the toxic activities of all other Lachesis species. Combining immunochemical methods, sec-
ond generation antivenomics, and venom neutralization tests we have unveiled the efficacy
of two therapeutic polyvalent antivenoms and three experimental monospecific antivenoms
to recognize the complete proteomes and neutralize the hemorrhagic, coagulant, proteolytic
and lethal activities from three different Lachesis species from different geographic popula-
tions. The results demonstrate that antivenoms raised by immunizing horses with the ven-
oms of different Lachesis species are effective in the neutralization of congeneric venoms
Fig 7. Immunoaffinity chromatography-based antivenomic analysis of the immunoreactivity of
polyspecific and monospecific antivenoms towards the venom of L. muta muta from Tucurui (Brazil).
Panels display reverse-phase separations of whole venom components, and non-retained (A, C, E, G, and I)
and the retained (B, D, F, H, and J) fractions recovered, respectively, from the affinity columns of immobilized
BCL, BL, AL, AB, and AC antivenoms. Panels K and L, non-retained and retained venom fractions by
immobilized equine control immunoglobulins. CRISP, cysteine-rich secretory protein; other acronyms as in
the legend of Fig 2.
https://doi.org/10.1371/journal.pntd.0005793.g007
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not used in the immunization mixture, indicating that they could be used equivalently for
the clinical treatment of any lachesic envenoming. Owing to the similar clinical presenta-
tions of envenomings by Lachesis sp. and Bothrops sp., the use of polyvalent antivenoms
which include the Lachesis component is therefore recommended in Latin America.
Table 2. Neutralization of the proteolytic activity of Lachesis venoms by polyspecific BCL and BL and monospecific antivenoms.
ED50 (μL/mg)
Venom BCL BL AL AB AC
L. stenophrys 876.1 ± 21.32 a* 473.0 ± 9.19 b 2183.2 ± 13.72c nn1 nn1
L. melanocephala 229.0 ± 3.67 a 169.9 ± 4.73 b 651.2 ± 34.72 c nn2 3334.9 ± 377.06d
L. m. muta Colombia 789.1 ± 21.67 a 293.5 ± 8.04 b 1736.5 ± 36.75 c nn1 nn1
L. m. muta Peru´ 375.9 ± 12.47 a 148.5 ± 8.99 b 1240.1 ± 49.19 c nn1 nn1
L. m. muta Cascalheira 538.3 ± 26.50 a 241.5 ± 11.52 b 1616.1 ± 79.33 c nn1 nn1
L. m. muta Tucurui 861.9 ± 35.00 a 221.9 ± 6.70 b 1375.6 ± 18.30 c nn1 nn1
L. m. rhombeata Recife 592.3 ± 19.98 a 219.2 ± 5.36 b 1422.2 ± 152.25 c nn1 nn1
1 nn, no neutralization at ratio 4000 μL antivenom/mg venom.
2 No neutralization at ratio 3600 μL antivenom/mg venom.
BCL: polyspecific anti-bothropic, anti-crotalic, anti-lachesic ICP antivenom; BL: anti-bothropic and anti-lachesic antivenom from Instituto Vital Brazil; AL,
monospecific anti-lachesic antivenom; AB, monospecific anti-bothropic antivenom; AC, monospecific anti-crotalic antivenom.
*Values with different superscripts are significantly different for the various antivenoms against a single venom (p<0.05).
https://doi.org/10.1371/journal.pntd.0005793.t002
Fig 8. Immunoaffinity chromatography-based antivenomic analysis of the immunoreactivity of
polyspecific and monospecific antivenoms towards the venom of L. muta rhombeata from Brazil.
Panels display reverse-phase separations of whole venom components, and non-retained (A, C, E, G, and I)
and the retained (B, D, F, H, and J) fractions recovered, respectively, from the affinity columns of immobilized
BCL, BL, AL, AB, and AC antivenoms. Panels K and L, non-retained and retained venom fractions by
immobilized equine control immunoglobulins. CRISP, cysteine-rich secretory protein; other acronyms as in
the legend of Fig 2.
https://doi.org/10.1371/journal.pntd.0005793.g008
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Table 3. Neutralization of the hemorrhagic effect of Lachesis venoms by polyspecific BCL and BL and monospecific antivenoms.
ED50 (μL/mg)
Venom/Antivenom BCL BL AL AB AC
L. stenophrys 238.7 ± 25.57 a* 84.7 ± 3.23b 508.9 ± 63.91c 2289.0 ± 253.90d nn1
L. melanocephala 371.3 ± 5.80 a 120.8 ± 10.3 b 591.3 ± 9.70 c 3258.3 ± 210.40 d nn1
L. m. muta Colombia 224.6 ± 26.48 a 88.3 ± 11.72 b 777.9 ± 105.43 c nn1 nn1
L. m. muta Peru´ 251.7 ± 26.23 a 43.9 ± 11.00 b 917.1 ± 245.13 c nn1 nn1
L. m. muta Cascalheira 291.3 ± 30.10 a 68.6 ± 0.50 b 2564.8 ± 239.40 c nn1 nn1
L. m. muta Tucurui 225.2 ± 53.18 a 111.9 ± 18.46 b 472.4 ± 53.08 c nn1 nn1
L. m. rhombeata Recife 314.5 ± 7.52 a 53.2 ± 9.90 b 581.5 ± 41.54 c nn1 nn1
1 nn, no neutralization at ratio 4000 μL antivenom/mg venom.
BCL: polyspecific anti-bothropic, anti-crotalic, anti-lachesic ICP antivenom; BL: anti-bothropic and anti-lachesic antivenom from Instituto Vital Brazil; AL,
monospecific anti-lachesic antivenom; AB, monospecific anti-bothropic antivenom; AC, monospecific anti-crotalic antivenom.
*Values with different superscripts are significantly different for the various antivenoms against a single venom (p<0.05).
https://doi.org/10.1371/journal.pntd.0005793.t003
Table 4. Neutralization of coagulant effect of Lachesis venoms by polyspecific BCL and BL and monospecific antivenoms.
ED (μL/mg)
Venom/Antivenom BCL BL AL AB AC
L. stenophrys 708.1 ± 10.34a* 141.1 ± 4.73 b 651.6 ± 14.34 c nn1 nn1
L. melanocephala 514.2 ± 2.08 a 109.9 ± 4.04 b 660.9 ± 3.13 c nn1 nn1
L. m. muta Colombia 752.2 ± 36.7 a 336.0 ± 21.3 b 1039.6 ± 15.8 c nn1 nn1
L. m. muta Peru´ 1322.7 ± 30.1 a 209.8 ± 10.2 b 1701.1 ± 52.9 c nn1 nn1
L. m. muta Cascalheira 1341.3 ± 175.4 a 222.8 ± 8.80 b 1269.1 ± 78.40 a nn1 nn1
L. m. muta Tucurui 726.5 ± 24.86 a 138.4 ± 1.11 b 836.4 ± 3.72 c nn1 nn1
L. m. rhombeata Recife 846.2 ± 6.60 a 463.8 ± 1.50 b 1563.1± 32.3 c nn1 nn1
1 nn, no neutralization at ratio 4000 μL antivenom/mg venom.
BCL: polyspecific anti-bothropic, anti-crotalic, anti-lachesic ICP antivenom; BL: anti-bothropic and anti-lachesic antivenom from Instituto Vital Brazil; AL,
monospecific anti-lachesic antivenom; AB, monospecific anti-bothropic antivenom; AC, monospecific anti-crotalic antivenom.
*Values with different superscripts are significantly different for various antivenoms against a single venom (p<0.05).
https://doi.org/10.1371/journal.pntd.0005793.t004
Table 5. Neutralization of lethality of Lachesis venoms by polyspecific BCL and BL and monospecific antivenoms*.
Venom/Antivenom BCL BL AL AB AC
L. stenophrys + + + + -
L. melanocephala + + + - -
L. m. muta Colombia + + + - -
L. m. muta Peru + + + - -
L. m. muta Cascalheira + + + + -
L. m. muta Tucurui + + + - -
L. m. rhombeata Recife + + + + -
*Results are represented by capacity of antivenoms to protect mice at a ratio of 500 μL antivenom/mg venom.
BCL: polyspecific anti-bothropic, anti-crotalic, anti-lachesic ICP antivenom; BL: anti-bothropic and anti-lachesic antivenom from Instituto Vital Brazil; AL,
monospecific anti-lachesic antivenom; AB, monospecific anti-bothropic antivenom; AC, monospecific anti-crotalic antivenom.
(+) indicates neutralization and (-) indicates lack of neutralization.
https://doi.org/10.1371/journal.pntd.0005793.t005
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Supporting information
S1 Fig. Titration curves for mono and polyspecific antivenoms against Lachesis venoms.
Antivenoms were serially diluted by a factor of 3 (starting from a dilution of 1/500) and tested
by ELISA against the following crude Lachesis venoms: L. stenophrys from Costa Rica (A), L.
melanocephala from Costa Rica (B), L. muta muta from Colombia (C), Peru (D), the Brazil
regions of Cascalheria (E), Tucurui (F), and L. muta rhombeata from Recife, Brazil (G). Anti-
venom acronyms, BCL, polyspecific anti-bothropic, anti-crotalic, anti-lachesic antivenom
from Instituto Clodomiro Picado (Cr); BL, anti-bothropic and anti-lachesic antivenom from
Instituto Vital Brazil, Nitero´i, Brazil; AL, monoespecific anti-lachesic antivenom; AB, monoe-
specific anti-bothropic antivenom; AC, monoespecific anti-crotalic antivenom. Each point
represents the mean ± SD of three independent determinations.
(DOCX)
S1 Table. Proteomic identification of 2DE resolved proteins from Costa Rican L. ste-
nophrys venom.
(DOCX)
S2 Table. 2DE-separated L. stenophrys venom protein spots recognized by mono and poly-
specific antivenoms.
(DOCX)
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